In oncology, and especially in the treatment of non-small-cell lung cancer (NSCLC), dose
optimization is often a neglected part of precision medicine. Many drugs are still being …

In the modern era of cancer treatment, with targeted agents superseding more traditional
cytotoxic chemotherapeutics, it is becoming increasingly important to use stratified medicine …

In this article, the challenges and strategies of phase 1 drug development for lung cancer
are discussed. These include the use of precise dose determinations via statistical …

Osimertinib is a mutant-selective EGFR inhibitor that is effective against non-small cell lung
cancer (NSCLC) in patients with the EGFR-T790M mutation, who are resistant to EGFR …

Objective To estimate the cost-effectiveness of sequences starting with tyrosine kinase
inhibitors (TKI), afatinib and osimertinib, for the treatment of epidermal growth factor receptor …

Background: Studies have reported that advanced NSCLC benefits from celecoxib
combined with systematic treatment. However, the optimal combination with different …

Therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for
patients with EGFR-mutated non-small cell lung cancer (NSCLC) has been shown to have …

Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …

What is known and objective The efficacy of epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR‐TKIs) in patients diagnosed with non–small‐cell lung cancer (NSCLC) has …

Among treatment modalities for lung cancer, the most promising therapy is the use of
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs). Both erlotinib and …